Open AccessP972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC‐1 VERSUS PHYSICIAN'S CHOICE OF THERAPY IN LONG‐TERM FOLLOW‐UP OF TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN DARATUMUMAB TRIALS
Author(s) -
Weisel K.,
Chari A.,
Usmani S. Z.,
Goldschmidt H.,
Mateos M.V.,
Qi K.,
Londhe A.,
Nair S.,
Lin X.,
Pei L.,
Ammann E.,
Kobos R.,
Smit J.,
Parekh T.,
Slavcev M.,
Moreau P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846756.44372.25
Subject(s) - medicine , daratumumab , population , oncology , clinical trial , multiple myeloma , surgery , lenalidomide , environmental health